Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

17 children suffering from neurodermatitis, aged 2 to 14 years, were treated with ketotifen at a dosage of 1 mg twice daily. In 7 children polyvalent therapy was given. Ketotifen therapy produced a pronounced alleviation of the itching within only two weeks and the patients became entirely itching free after 20 days on an average. The improvement of skin lesions appeared after two months of treatment. Patients became entirely skin lesions free between seven and nine months. In three patients the deterioration of skin lesions was triggered with infection. With regard to long-lasting of Ketotifen therapy, the side effects were not observed.
 ...
PMID:Effectiveness of ketotifen in the treatment of neurodermatitis in childhood. 212 29

3 patients with generalized neurofibromatosis were treated with the mast cell blocking substance Ketotifen. Pruritus and pain could be inhibited significantly and the tumor growth could be prevented.
 ...
PMID:[Ketotifen inhibits urticaria and tumor progression in neurofibromatosis]. 251 Oct 44

A double-blind study was performed in 305 patients to compare ketotifen capsule and clemastine tablet. Ketotifen alleviated eruption and itching to a significantly greater extent than clemastine. The utility rating of ketotifen was significantly higher than that of clemastine.
 ...
PMID:Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. 265 May 86

A double-blind comparative study was performed to investigate the usefulness of ketotifen syrup as compared with clemastine syrup in 284 patients with atopic dermatitis. The clinical efficacy of ketotifen was significantly superior to that of clemastine. Ketotifen alleviated not only pruritus but also other dermatologic symptoms.
 ...
PMID:Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. 266 Jun 32

Ketotifen, benzocycloheptathiophene, (Zaditen) an orally active, anti-allergic and anti-asthmatic drug in a dose of 1 mg twice daily was given from 2 to 20 months in 20 selected patients with food allergy (FA) or food intolerance (FI). Sixteen children and four adults of which ten had atopic dermatitis (AD), six urticaria or/and angiooedema (two of which with oropharynx pruritus, oedema of the lips and anaphylactic shock), two asthma, and two gastrointestinal disorders. Food allergy was proved by clinical history, exclusion diet positive challenge test, skin prick tests (SPT) total IgE (PRIST) and specific IgE (RAST). Gastrointestinal permeability was measured in 5 out of 20 patients using mannitol and lactulose as probe molecules on three occasions: (1) by ingestion of the markers alone, (2) with concomitant ingestion of the offending food(s), and (3) with previous administration of ketotifen (2 mg) six hours before ingestion of markers and offending food. In all five individuals, food ingestion resulted in a significant rise of lactulose: mannitol urinary ratio and previous administration of ketotifen resulted in a normalization of the mannitol:lactulose urinary ratio. Patients with urticaria and/or angiooedema, gastrointestinal symptoms, asthma, and oropharynx pruritus with oedema of the lips were completely protected. In patients with AD, 70% were greatly improved or improved but 30% remained the same. It is our impression that ketotifen offers a new therapeutic dimension and therapy in FA.
 ...
PMID:Ketotifen in prevention and therapy of food allergy. 368 73

Forty patients with urticaria, 13 with cholinergic urticaria, 22 with urticaria factitia, and 5 with both types of urticaria, were treated with ketotifen or placebo in a double-blind crossover study. Five patients dropped out, one because of excessive weight gain. In 23 of 24 patients with urticaria factitia, ketotifen caused a marked reduction of wealing and pruritus. In contrast, only 62% of the patients with cholinergic urticaria noticed a reduction of wealing, and 69% had reduced itching. Ketotifen caused few side effects, the most frequent one being mild tiredness in 9% of the patients. The beneficial effect of ketotifen in urticaria factitia and cholinergic urticaria may be due to its ability to reduce the liberation and the effectiveness of mast cell mediators.
 ...
PMID:[Effect of ketotifen in urticaria factitia and urticaria cholinergica in a crossover double-blind trial]. 390 13

21 patients suffering from chronic urticaria were treated with Ketotifen (2 X 1 mg/d) for 4 weeks. The suppression of weals and pruritus, the side effects in comparison with antihistamines, as well as the effect after finishing therapy have been studied. Ketotifen has a good suppressing effect on weals and pruritus. The general tolerance of the preparation is good, as well. Thus Ketotifen may be regarded as an additional possibility concerning treatment of chronic urticaria.
 ...
PMID:[Ketotifen treatment of chronic urticaria. An open study of therapeutically difficult courses]. 409 May 77

We report a case of diffuse erythrodermic cutaneous mastocytosis with bone marrow infiltration. An 11-month-old female patient was referred to our hospital for intermittent flushing, fever, intense itching, erythematous rash and bullous lesions. Cutaneous biopsy demonstrated diffuse cutaneous mastocytosis. The bone marrow aspirate revealed mast cell infiltration. Ketotifen treatment was very effective.
 ...
PMID:Diffuse erythrodermic cutaneous mastocytosis with bone marrow infiltration. 835 1

Ketotifen fumarate, formulated for the treatment of allergic conjunctivitis, is a histamine H1-receptor antagonist, mast cell stabilizer, and eosinophil inhibitor (decreases chemotaxis and activation of eosinophils). In this study, healthy volunteers 3 years of age or older received ketotifen fumarate .025% ophthalmic solution (n = 330) or placebo (n = 165) four times daily for 6 weeks. Ketotifen was safe and well tolerated in the adult and pediatric populations, with an incidence of ocular adverse events of 18.2%, compared with 15.2% with placebo. No ocular rebound vasodilation or itching was observed within 48 hours after treatment. Ketotifen has a favorable safety and tolerability profile, which may have a positive impact on compliance, an important aspect of effective symptomatic control of allergic conjunctivitis.
 ...
PMID:Ocular tolerability and safety of ketotifen fumarate ophthalmic solution. 1243 Oct 41

The increasing resistance of Plasmodium falciparum to chloroquine (CQ) has created urgent needs for the evaluation of alternative antimalarial drugs that are effective, safe, readily available and affordable. Ketotifen, a histamine H(1)-receptor antagonist that reverses CQ resistance in P. falciparum in vitro, may potentially enhance the effects of CQ in vivo. The effects of oral treatment with CQ alone (30 mg/kg base given over 3 days) were compared with those of this CQ regimen combined with ketotifen fumarate (0.25 mg at presentation followed by 0.125 mg/kg every 8 h for 5 days). The subjects were 145 children aged 1-10 years who were suffering from acute, symptomatic, uncomplicated, P. falciparum malaria: 74 given CQ alone and 71 given CQ plus ketotifen (CQK). Although the mean fever-clearance time was significantly shorter following treatment with CQK than after treatment with CQ alone, all other therapeutic responses were similar in the two treatment groups. Among siblings in whom there was clustering of infections, the likelihood of cure was also similar in the two treatment groups. Retreatment of 17 CQ-treatment failures with CQK produced a cure in six children, and retreatment of 22 CQK-treatment failures with CQK produced a cure in eight children. Retreatment of all drug failures with a combination of amodiaquine plus pyrimethamine-sulfadoxine resulted in complete clearance of parasitaemia and symptoms within 2-3 days and a cure 'rate' of 100% on day 28. The prevalences and intensities of gametocytaemias on day 3 or days 3, 7 and/or 14 combined were similar in the two groups. Adverse drug reactions were always tolerable, and limited to pruritus, gastro-intestinal disturbances, drowsiness and weight gain; the latter two adverse effects were significantly more frequent in those treated with CQK than in those given CQ alone. Haematological and biochemical parameters were not adversely affected by either treatment regimen. The findings indicate that - at least at the dosing regimen used in the present study and among children with acute, uncomplicated, P. falciparum malaria from Ibadan - the addition of ketotifen to CQ produced little or no significant enhancement of the antimalarial effect of CQ.
 ...
PMID:A randomized comparison of chloroquine and chloroquine plus ketotifen in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. 1280 65


1 2 Next >>